Drug Profile
Exenatide pegylated analogue - PegBio
Alternative Names: PB-119; PEG-exenatide; Polyethylene glycol exenatide - PegBioLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator PegBio
- Class Antidementias; Antiglaucomas; Antihyperglycaemics; Antiparkinsonians; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 05 Apr 2024 PegBio plans a phase I/II trial for Obesity (SC) in May 2024 (NCT06350812),
- 02 Oct 2023 Efficacy and adverse events data from a phase III trial in Type 2 diabetes mellitus presented at the European Association for the Study of Diabetes (EASD-2023)
- 23 Jun 2023 Efficacy and adverse events data from a phase III trial in Type 2 diabetes mellitus presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA-2023)